WITHDRAWN: Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens

AUTHORS

Jamshid Vafaeimanesh 1 , 2 , Fahimeh Safarnezhad Tameshkel 1 , Hossein Ajdarkosh 1 , Azita Azarkeyvani 3 , Mahmoodreza Khoonsari 1 , Amirhossein Faraji 1 , Masoudreza Sohrabi 1 , Sima Aten 1 , Hossein Keyvani 1 , Farhad Zamani 1 , *

1 Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, IR Iran

2 Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, IR Iran

3 Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Department of Thalassemia Clinic, Tehran, IR Iran

How to Cite: Vafaeimanesh J, Safarnezhad Tameshkel F, Ajdarkosh H, Azarkeyvani A, Khoonsari M, et al. WITHDRAWN: Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens, Hepat Mon. Online ahead of Print ; 18(9):e66419. doi: 10.5812/hepatmon.66419.

ARTICLE INFORMATION

Hepatitis Monthly: 18 (9); e66419
Published Online: July 11, 2018
Article Type: Research Article
Received: January 17, 2018
Revised: June 5, 2018
Accepted: June 9, 2018
Crossmark

Crossmark

CHEKING

READ FULL TEXT

Withdrawal Note

This article is withdrawn by EIC - on behalf of the editorial board- because of the case that it was published simultaneously in another journal (https://www.ncbi.nlm.nih.gov/pubmed/30084415). After the investigation raised by EIC, authors confessed to their mistake in double submission (#346818) and due to the status of the article (In Press) and journal policy about withdrawal regulations (http://hepatmon.com/en/knowledgebase/category/tree.html#withdrawal_regulations.html), we decided to withdraw it from our journal.

COMMENTS

LEAVE A COMMENT HERE: